SCHEMBL2833987

SCHEMBL2833987

CC#CCc1c(F)ccc(C(=O)O)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
MAP2K1 Q02750 2/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
MAP2K2 P36507 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ASPH Q12797 1/20 0.34
KDM8 Q8N371 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ALB P02768 1/20 0.33
RARB P10826 2/20 0.32
RARA P10276 1/20 0.32
RARG P13631 1/20 0.32
ADRA2A P08913 1/20 0.31
CLCN2 P51788 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11853277 0.81 CYP1A2 (0.46) CYP1A2CA12CA9KDM4ESMN1; SMN2
SCHEMBL2831435 0.81 ALB (0.47) CA12CA9CES2CES1KDM4E
SCHEMBL1541651 0.78 CES2 (0.41) CYP1A2MAP2K1CES2CES1MAP2K2
SCHEMBL16850337 0.75 CES2 (0.42) CYP1A2MAP2K1CES2CES1MAP2K2
SCHEMBL2833475 0.74 MRGPRX4 (0.43) CA12CA9KDM4ESMN1; SMN2NPC1
SCHEMBL2832604 0.74 MEN1 (0.33)
SCHEMBL2834374 0.71 DPP4 (0.31) CYP1A2CA12CA9EPHX2NR1H4
SCHEMBL2834382 0.71 DCLRE1B (0.42) CYP1A2CA12CA9CES2CES1
SCHEMBL2832593 0.71 CES2 (0.35) CYP1A2MAP2K1CES2CES1MAP2K2
SCHEMBL241797 0.68 CES2 (0.70) CYP1A2CA12CA9MAP2K1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 CYP1A2 3539/4885CA12 71/4885CA9 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.